Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes

Daniëlle Hijdra¹,², Adriane DM Vorselaars², Jan C Grutters²,³, Anke ME Claessen¹,² and Ger T Rijkers¹,²,⁴*

Abstract

Background: Three subpopulations of monocytes can be distinguished in human blood: classical (CD14⁺⁺CD16⁻), intermediate (CD14⁺⁺CD16⁺), and nonclassical (CD14⁺CD16⁺⁺). CD16 expressing monocytes are expanded in patients with sarcoidosis and in various other inflammatory diseases. In sarcoidosis, it is unclear whether either intermediate, nonclassical or both CD16 expressing monocytes are responsible for this increase. Data relating to the monocyte subpopulations is receiving increasing attention, but the expression of TNF receptors on these subpopulations has not been studied thus far. The aim of this study was to determine frequencies of monocyte subpopulations and their expression of TNFR1 and TNFR2 in both sarcoidosis patients and healthy controls.

Methods: Peripheral blood cells of sarcoidosis patients and healthy controls were stained for the markers HLA-DR, CD14, CD16, CD120a and CD120b. Cells were measured on a FACSCalibur and analyzed with FlowJo. We used Student’s t-test and a parametric One-way ANOVA for statistical analysis.

Results: Sarcoidosis patients had a significant higher frequency of intermediate monocytes than healthy controls. Significant differences in TNF receptor expression were found between the monocyte subpopulations, both in sarcoidosis patients as well as in healthy controls: intermediates expressed more TNFR1 than classicals and nonclassicals and nonclassicals expressed more TNFR2 than intermediates, whereas intermediates showed higher expression than classicals.

Conclusions: In both sarcoidosis patients and healthy controls intermediate monocytes show the highest expression level of TNFR1 among monocyte subpopulations and nonclassical monocytes show the highest expression level of TNFR2. These findings, as well as the higher frequency of intermediate monocytes in sarcoidosis patients, provide evidence for the existence of two functionally-distinct CD16 expressing monocyte subpopulations.

Keywords: Monocytes, CD120a, CD120b, TNF receptor, CD14, CD16, HLA-DR, Peripheral blood, Sarcoidosis

Background

Monocytes originate from myeloid progenitors in the bone marrow, circulate in the blood for up to three days, and then enter peripheral tissues where they differentiate into macrophages or dendritic cells [1].

Human monocytes can be divided into three subpopulations: classical, intermediate, and nonclassical. This subdivision is based on the expression levels of the lipopolysaccharide (LPS) coreceptor CD14 and the Fcγ receptor III CD16. Classical monocytes, the major population of monocytes, are CD14⁺⁺CD16⁻. The minor population of CD16 expressing monocytes are further subdivided in intermediate monocytes (CD14⁺⁺CD16⁺) and nonclassical monocytes (CD14⁺CD16⁺⁺) [2]. Recently, monocyte subpopulations have been extensively investigated. In addition to CD14 and CD16, also other markers, such as HLA-DR, CCR2 and CCR5, can distinguish the three human monocyte subpopulations [3,4].

An imbalance in the relative proportion of CD16 expressing monocytes has been found in a variety of immune mediated diseases such as rheumatoid arthritis,
diabetes, atherosclerosis, bacterial and HIV infections (reviewed by Ziegler-Heitbrock [5]). An increase in the relative number of CD16 expressing monocytes was found in newly diagnosed sarcoidosis patients, suggesting an activated state of the monocytes. This activated state might be an indicator for disease activity [6,7]. These investigations have not discriminated between the two CD16 expressing monocyte subpopulations. Recently, it has been shown in patients with rheumatoid arthritis [8] and severe asthma [9] that intermediate monocytes are responsible for the increase in CD16 expressing monocytes. So far, this has not been investigated in patients with sarcoidosis.

Sarcoidosis is a systemic, granulomatous disease of unknown origin that primarily affects the lungs. It is a disease of all races and ethnic groups with varying incidence throughout the world [10-12]. The highest incidence of sarcoidosis in Europe has been reported from Sweden: 24 cases per 100,000 [13]. In The Netherlands, the incidence of sarcoidosis is estimated to be 20 cases per 100,000 [14]. In the United States, the incidence rate in black people is 36 cases per 100,000 compared to 11 cases per 100,000 in white people [15]. The most important feature of sarcoidosis is the formation of non-caseating granulomas [10-12].

In the human lung, tumor necrosis factor (TNF) is mainly produced by alveolar macrophages and thought to play a major role in the development of the granulomatous inflammation. The release of TNF is increased in the lung of patients with pulmonary sarcoidosis [16,17]. Therefore TNF is an attractive target for immunotherapy in sarcoidosis.

TNF exerts its function by binding to and signaling via two different receptors. TNFR1 (CD120a) is constitutively, but in low levels, expressed on nearly all nucleated cell types. TNFR2 (CD120b) is inducible and expressed by cells of myeloid lineage, peripheral T cells and alveolar lymphocytes and macrophages [18-23]. TNFR1 activates the caspase family, which induce cell death. TNFR2 signalling leads to NF-κB transcription and can induce proliferation, differentiation, cytokine production and even apoptosis. When TNFR1 and TNFR2 are co-expressed on the same cells, intracellular cross-talk between the receptors may occur [24]. Both TNF receptors can be enzymatically cleaved from the cell surface and form soluble TNF receptors. Soluble TNF receptors can neutralize TNF and clear it from the circulation and act as a TNF antagonist, but can also prolong its bioactivity by binding TNF and thus stabilize the trimeric structure [22]. Membrane-bound TNF binds more strongly to TNFR2 than soluble TNF does. It may be that TNFR2 only becomes fully activated with membrane-bound TNF [21].

There are a few reports of TNFR1 and TNFR2 expression on peripheral blood cells. Approximately 25% of the peripheral blood lymphocytes in healthy subjects is CD4+TNFR2+. Interestingly, in sarcoidosis the percentage of CD4+TNFR2+ cells is increased, especially in patients in remission or with stable disease (respectively 35% and 33%), which may indicate a role in down regulation of a cell-mediated immune response [23]. FoxP3+ T reg cells expressed the highest levels of TNFR2 among subsets of human peripheral blood CD4+ T cells and were able to shed large amounts of sTNFR2, suggesting an important role for T reg cells in suppressing TNF [25]. It is attractive to speculate about a similar role for one of the subpopulations of human monocytes. However, the expression of TNFR1 and TNFR2 on monocyte subpopulations has not been studied thus far.

The aim of the present study was to determine frequencies of the three monocyte subpopulations in peripheral blood of patients with sarcoidosis compared to healthy controls and the relative expression of TNFR1 and TNFR2 on these subpopulations.

Methods

Patients and healthy controls

Thirty-eight patients (11 female, 27 male; median age 48 years, range 22–70 years) with proven sarcoidosis were included in the present study. For this study, all
sarcoidosis patients were grouped as one, independent of severity of the disease and independent of use of medication. Thirteen healthy volunteers (4 female, 9 male; median age 50 years, range 27–58 years) were used as controls. Peripheral blood was collected in sodium heparin tubes. The study was approved by the medical ethical evaluation committee of the St Antonius Hospital in Nieuwegein, The Netherlands.

**Antibodies and flow cytometry**

Anti-HLA-DR FITC and anti-CD16 PE were obtained from BD Biosciences (San Diego, CA, USA). Anti-CD14 PerCP-eFluor710 was from eBioscience (San Diego, CA, USA). Anti-CD120a APC (TNFR1) and anti-CD120b APC (TNFR2) were from R&D Systems (Minneapolis, MN, USA). After staining, flow cytometry data were acquired on a FACSCalibur (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR, USA).

Monocytes were gated based on FSC x SSC and SSC x HLA-DR expression. Subsequently, monocytes were subdivided in three populations based on CD14 and CD16 expression pattern. We used fluorescence minus one (FMO) staining as control for the TNF receptor staining by substracting the MFI of the FMO control of the MFI of the TNF receptor.

**Statistical analysis**

Data are expressed as mean ± SEM. Comparison of two groups of data (patients versus controls) was performed by a two-tailed Student’s t-test and comparison of three groups of data (subpopulations of monocytes) was performed by a parametric One-way ANOVA, both by using GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA). Differences were considered statistically significant at \( P \) values of 0.05 or less.

**Results and discussion**

**Monocytes subpopulations**

The frequency of classical, intermediate, and nonclassical monocyte subpopulations was analyzed in 38 sarcoidosis patients and 13 healthy controls. Median fluorescence intensity (MFI) of HLA-DR, CD14, and CD16 on monocyte subpopulations in sarcoidosis patients and healthy controls is shown in Figure 2. The data in panel A are regrouped in panel B to allow better comparison between the monocyte subpopulations. Values are expressed as mean ± SEM. All three markers were significantly different between the three monocyte subpopulations. Between sarcoidosis patients and healthy controls, nonclassical monocytes showed significant different levels of HLA-DR expression and classical monocytes showed significant different levels of CD14 expression. Comparison of three groups of data (subpopulations of monocytes) was performed by a parametric One-way ANOVA and comparison of two groups of data (patients versus controls) was performed by a two-tailed Student’s t-test.

![Figure 2](http://www.journal-inflammation.com/content/9/1/38)
patients and 13 healthy controls, based on HLA-DR, CD14 and CD16 expression pattern. In this study, classical monocytes accounted for 60–90% of SSC x HLA-DR+ gated monocytes, intermediate monocytes for about 2–5% and nonclassical monocytes for 5–25%, both in sarcoidosis patients as well as in healthy controls. Others (reviewed by Ziegler-Heitbrock [5]) have found increased or decreased relative numbers of CD16 expressing monocytes in a variety of inflammatory and/or infectious diseases in man. In most of these studies nonclassical and intermediate monocytes were grouped together as one subpopulation. Rossol et al. reported that increased frequencies of CD16 expressing monocytes in rheumatoid arthritis were due to an increase in intermediates [8]. Moniuszko et al. reported similar findings for severe asthma [9]. We also found a higher frequency of intermediate monocytes in sarcoidosis patients (3.08% ± 0.25%) than in healthy controls (1.98% ± 0.22%; P = 0.017; Figure 1), while nonclassical monocytes were not increased (data not shown). It should be stressed that CD16 expressing monocytes should be considered as two different populations.

All three monocyte subpopulations differed significantly in HLA-DR expression, both in sarcoidosis patients as well as in healthy controls. Intermediates showed the highest expression of HLA-DR, followed by nonclassicals (P < 0.0001; Figure 2A). This differential expression of HLA-DR on monocyte subpopulations previously has been described for patients with rheumatoid arthritis [8] and for healthy controls [3].

We found significant differences in HLA-DR and CD14 expression between patients with sarcoidosis and healthy controls. Nonclassical monocytes of sarcoidosis patients expressed a higher level of HLA-DR than nonclassicals of controls (P = 0.026; Figure 2B). Classical monocytes of sarcoidosis patients expressed a lower level of CD14 than classicals of healthy controls (P = 0.030; Figure 2C). Intermediate monocytes of sarcoidosis patients tended to have a higher level of HLA-DR and a lower level of CD14 than intermediates of healthy controls (Figures 2B and 2C). Nonclassical and intermediate monocytes of sarcoidosis patients tended to have a higher level of CD16 than nonclassicals and intermediates of controls (Figure 2D).

**TNF receptors**

TNF is a major cytokine regulating the activity of monocytes and therefore we have extended the phenotypic characterization of monocyte subpopulations for expression of TNF receptors. Although no differences were found between patients and controls, analysis of TNFRI and TNFR2 revealed differential expression on the monocyte subpopulations, both in sarcoidosis patients as well as in healthy controls. All monocytes expressed TNFRI, but intermediates showed a higher expression of TNFRI than classicals and nonclassicals (P < 0.05; Figure 3A). All monocytes also expressed TNFRII, but the three subpopulations showed major differences in TNFRII expression (P < 0.0001; Figure 3B). Nonclassical monocytes expressed the highest levels of TNFRII. Intermediates expressed less TNFRII than nonclassicals, but more than classicals. Although classical monocytes expressed the lowest levels of TNFRII, values were still largely positive compared to a fluorescence minus one (FMO) control.
Conclusions
Subpopulations of monocytes not only express different levels of CD14, CD16 and HLA-DR, but also different levels of TNFR1 and TNFR2. This finding is new and emphasizes the diversity and potential different functions of the three monocyte subpopulations. Frequencies of intermediate monocytes are increased in sarcoidosis patients, suggesting an activated state of the monocytes in this disease. This finding may be of especial relevance because intermediate monocytes expresses the highest level of HLA-DR among the monocyte subpopulations. This activated state might be a novel indicator for disease activity. Intermediate monocytes also express the highest level of TNFR1 among the monocyte subpopulations, while nonclassical monocytes, the other CD16 expressing monocyte subpopulation, express the highest level of TNFR2. This data supports the evidence of two functionally-distinct CD16 expressing monocyte subpopulations.

HLA-DR may be a valuable marker to monitor the disease course of sarcoidosis patients. Intermediate and nonclassical monocytes plus their TNF receptor expression pattern might be relevant to monitor for sarcoidosis patients who are going to be treated with anti-TNF (Remicade), as well as for other patients on anti-TNF therapy, such as those suffering from rheumatoid arthritis, psoriasis or Crohn’s disease. Prospective monitoring of these patients should demonstrate whether particular monocyte subpopulations display differential sensitivity to this form of treatment and whether this correlates with the clinical response.

Abbreviations
ANOVA: Analysis of variance; FACS: Fluorescence activated cell sorter; FMO: Fluorescence minus one; HIV: Human immunodeficiency virus; LPS: Lipopolysaccharide; NFI: Median fluorescence intensity; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; SEM: Standard error of the mean; SSC: Side scatter; TNF: Tumor necrosis factor alpha; TNFR1: Tumor necrosis factor receptor 1; TNFR2: Tumor necrosis factor receptor 2.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DH performed experiments, designed the research protocols, analyzed data and wrote the manuscript. AV selected patients and collected blood samples. KG selected patients and designed the research protocols. AC and wrote the manuscript. AV selected patients and collected blood samples. JG selected patients and designed the research protocols. GR designed the research protocols. All authors interpreted data, edited the manuscript, read and approved the final manuscript.

Acknowledgements
This work was supported by the Innovation Fund of the St. Antonius Hospital in Nieuwegein, The Netherlands.

Author details
1Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands. 2Centre for Interstitial Lung Diseases, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands. 3Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. *Department of Sciences, Roosevelt Academy, Middelburg, The Netherlands.

Received: 13 April 2012 Accepted: 3 October 2012 Published: 5 October 2012

References
1. Tacke F, Randolph GJ: Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006, 211:609–618.
2. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB: Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e174–e280.
3. Wong KL, Tai JY, Wong WC, Han H, Sem X, Yeap WH, Koulisfki P, Wong SC: Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011, 118:e131–e131.
4. Ziegler-Heitbrock L: The CD14+CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007, 81:589–592.
5. Heron M, Grutters JC, van Velzen-Blad H, Velkamp M, Claessen AM, van den Bosch JH: Increased expression of CD16, CD69, and very late antigen-1 on blood monocytes in active sarcoidosis. Chest 2008, 134:1001–1008.
6. Okamoto H, Mizuno K, Horio T: Circulating CD14+CD16+ monocytes are expanded in sarcoidosis patients. J Dermatol 2003, 30:503–509.
7. Rossl M, Kraus S, Pfefer M, Baerwald C, Wagner U: The CD14brightCD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 2012, 64:671–677.
8. Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D, Dabrowska M: Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol 2009, 130:338–346.
9. Grutters JC, Drent M, van den Bosch JIM: Sarcoidosis. Eur Resp Mon 2009, 46:126–154.
10. Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Rottoli P, Spagnolo P, Teirstein A: Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vascul Dis Lung 2011, 28:56–64.
11. Milman N, Selleo C: Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis 1990, 750–57.
12. Kamphuis LS, van Laar JA, Missotten T, Thio HB, van Hagen PM: Sarcoidosis: changing insights in therapy. Ned Tijdschr Geneeskd 2010, 154:A1685.
13. Baughman RP, Teirstein AS, Judson MA, Lambiri I, Lower EE, Muller-Quernheim J, Prasse A, Rizzato G, Rotzoll P, Spagnolo P, Teirstein A: Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vascul Dis Lung 2011, 28:56–64.
14. Milman N, Selleo C: Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis 1990, 750–57.
15. Kamphuis LS, van Laar JA, Kuijpers M, Thiob HB, van Hagen PM: Sarcoidosis: changing insights in therapy. Ned Tijdschr Geneeskd 2010, 154:A1685.
16. Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Rottoli P, Spagnolo P, Teirstein A: Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vascul Dis Lung 2011, 28:56–64.
17. Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E, Pabst R, Müller-Quernheim J, Kratzer G, Chemiak R: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164:1885–1889.
18. Zola H, Fligo L, Weeden H: Expression of membrane receptor for tumour necrosis factor alpha in patients with sarcoidosis. Eur Respir J 2003, 21:421–428.
19. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE: Release of tumour necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990, 115:36–42.
20. Zola H, Fligo L, Weeden H: Expression of membrane receptor for tumour necrosis factor on human blood lymphocytes. Immunol Cell Biol 1993, 71:281–288.
21. Gehr G, Gentz R, Brockhaus M, Loetscher H, Lesslauer W: Both tumour necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol 1992, 149:911–917.
20. Ye Q, Dai H, Sarria R, Guzman J, Costabel U: Increased expression of tumor necrosis factor receptors in cryptogenic organizing pneumonia. Respir Med 2011, 105:292–297.

21. Faustman D, Davis M: TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010, 9:482–493.

22. Aderka D, Engelmann H, Maer Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175:323–329.

23. Kieszko R, Krawczyk P, Chocholska S, Bojarska-Junak A, Jankowska O, Król A, Rolński J, Milanowski J: Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respir Med 2007, 101:645–654.

24. Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I, Scheurich P, Schmid JA, Wajant H: Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci 2002, 115:2757–2770.

25. Van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW, Toes RE: Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 2008, 180:2747–2751.

doi:10.1186/1476-9255-9-38
Cite this article as: Hijdra et al: Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes. Journal of Inflammation 2012 9:38.